Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

CTGF expression is indicative of better survival rates in patients with medulloblastoma

Cancer Gene Therapy volume 27, pages 378–382 (2020)Cite this article

Subjects

Abstract

Medulloblastoma (MB) is the most frequent malignant brain tumor in children and it is subgrouped into 4 entities (SHH, WNT, Group 3, and Group 4). Molecular pathways involved in these different subgroups still are evolving and can be of clinical relevance to therapy. The YAP1-CTGF axis is known to regulate cell proliferation, differentiation, and cell death; however, its role in MB is poorly explored. We aimed to investigate the role of YAP1 gene in the MB SHH cell line DAOY and evaluate cell proliferation, doubling time and 3D spheroids invasion and its consequence on CTGF regulation. We assessed CTGF expression from 22 children with MB. Lastly, we validated our findings through in silico analysis in large cohorts dataset of patients. We observed an increased invasion rate of DAOY cells and CTGF downregulation under YAP1 knockdown (p < 0.0001). Additionally CTGF is overexpressed in MB with extensive nodularity subtype and an indicative of higher survival rates in pediatric MB (p < 0.05). Interestingly, no difference of CTGF expression was observed between molecular subgroups. These results provide new evidence ofCTGF as a potential prognostic marker for MB, corroborating to the role of YAP1 in restricting MB cell.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B. et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017;31(Issue 6):737–754.

    Article  CAS  Google Scholar 

  2. Martirosian V, Chen TC, Lin M, Neman J. Medulloblastoma initiation and spread: where neurodevelopment, microenvironment and cancer cross pathways. J Neurosci Res. 2016;94:1511–9.

    Article  CAS  Google Scholar 

  3. Fernandez-L A, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, et al. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev. 2009;23:2729–41.

    Article  CAS  Google Scholar 

  4. Fernandez-L A, Squatrito M, Northcott P, Awan A, Holland EC, Taylor MD, et al. Oncogenic YAP promotes radioresistance and genomic instability inmedulloblastoma through IGF2-mediated Akt activation. Oncogene. 2012;31:1923–37.

    Article  CAS  Google Scholar 

  5. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24:862–74.

    Article  CAS  Google Scholar 

  6. Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohortstudy. Lancet Oncol. 2017;18:958–71.

    Article  CAS  Google Scholar 

  7. Juan WC, Hong W. Targeting the hippo signaling pathway for tissue regeneration and cancer therapy. Genes. 2016;7:pii: E55.

    Article  Google Scholar 

  8. Low BC, Pan CQ, Shivashankar GV, Bershadsky A, Sudol M, Sheetz M, et al. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett. 2014;588:2663–70.

    Article  CAS  Google Scholar 

  9. Imajo M, Ebisuya M, Nishida E. Dual role of YAP and TAZ in renewal of the intestinal epithelium. Nat Cell Biol. 2015;17:7–19.

    Article  CAS  Google Scholar 

  10. Ma X, Wang H, Ji J, Xu W, Sun Y, Li W, et al. Hippo signaling promotes JNK-dependent cell migration. Proc Natl Acad Sci USA. 2017;114:1934–9.

    Article  CAS  Google Scholar 

  11. Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014;110:1698–704.

    Article  CAS  Google Scholar 

  12. Wang LH, Tsai HC, Cheng YC, Lin CY, Huang YL, Tsai CH, et al. CTGF promotes osteosarcoma angiogenesis by regulating miR-543/angiopoietin 2 signaling. Cancer Lett. 2017;391:28–37.

    Article  CAS  Google Scholar 

  13. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22:1962–71.

    Article  CAS  Google Scholar 

  14. Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012;23:785–93.

    Article  CAS  Google Scholar 

  15. Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang H, et al. Structural insights into the YAP and TEAD complex. Genes Dev. 2010;24:235–40.

    Article  CAS  Google Scholar 

  16. Cairns L, Tran T, Kavran JM. Structural insights into the regulation of hippo signaling. ACS Chem Biol. 2017;12:601–10.

    Article  CAS  Google Scholar 

  17. Chen L, Loh PG, Song H. Structural and functional insights into the TEAD-YAP complex in the Hippo signaling pathway. Protein Cell. 2010;1:1073–1083.

    Article  CAS  Google Scholar 

  18. Mesrouze Y, Bokhovchuk F, Meyerhofer M, Fontana P, Zimmermann C, Martin T, et al. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription fator TEAD. Elife. 2017;6:e25068.

    Article  Google Scholar 

  19. Jóźwiak J, Sontowska I, Bikowska B, Grajkowska W, Galus R, Roszkowski M, et al. Favourable prognosis in medulloblastoma with extensive nodularity is associatedwith mitogen-activated protein kinase upregulation. Folia Neuropathol. 2011;49:257–61.

    PubMed  Google Scholar 

  20. Korshunov A, Sahm F, Stichel D, Schrimpf D, Ryzhova M, Zheludkova O, et al. Molecularcharacterization of medulloblastomas with extensive nodularity (MBEN). Acta Neuropathol. 2018;136:303–13.

    Article  CAS  Google Scholar 

  21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.

    Article  CAS  Google Scholar 

  22. Kumar KS, Pillong M, Kunze J, Burghardt I, Weller M, Grotzer MA, et al. Corrigendum: computer-assisted quantification of motile and invasive capabilities of cancer cells. Sci Rep. 2018;8:46996.

    Article  Google Scholar 

  23. Cruzeiro GAV, Salomão KB, de Biagi CAO Jr, Baumgartner M, Sturm D, Lira RCP, et al. A simplified approach using Taqman low-density array for medulloblastoma subgrouping. Acta Neuropathol Commun. 2019;7:33.

    Article  Google Scholar 

  24. Garzia L, Kijima N, Morrissy AS, De Antonellis P, Guerreiro-Stucklin A, Holgado BL, et al. A hematogenous route for medulloblastoma leptomeningeal metastases. Cell. 2018;172:1050–1062.

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by FAPESP grant number 2017/06511–8, 2014/19976–0 and 2014/20341–0.

Author information

Authors and Affiliations

  1. Department of Oncology, Children’s Research Center, Neuro-Oncology group, University Children’s Hospital Zürich, August-Forel Strasse 1, CH-8008, Zürich, Switzerland

    Gustavo Alencastro Veiga Cruzeiro & Martin Baumgartner

  2. Department of Pediatrics, Ribeirão Preto Medical School, Hospital das Clínicas, University of São Paulo, Av.Bandeirantes 3900, Hospital das Clínicas, Ribeirão Preto, São Paulo, Brazil

    Gustavo Alencastro Veiga Cruzeiro, Regia Caroline Peixoto Lira, Carlos Alberto Scrideli, Elvis Terci Valera & Luiz Gonzaga Tone

  3. Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Cox 7, Boston, Massachusetts, USA

    Gustavo Alencastro Veiga Cruzeiro

  4. Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, São Paulo, Brazil

    Taciani de Almeida Magalhães

Authors
  1. Gustavo Alencastro Veiga Cruzeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Regia Caroline Peixoto Lira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taciani de Almeida Magalhães
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlos Alberto Scrideli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elvis Terci Valera
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Martin Baumgartner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Luiz Gonzaga Tone
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

G.A.V.C. planned and conducted all experiments, performed the in silico analysis, drafted, and critically read the manuscript. R.C.P.L conducted the overall survival analysis, helped to design the study, and critically read the manuscript. T.A.M., helped to review the design of the study, performed the in silico analysis, and critically read the manuscript. C.A.S. critically read the manuscript, M.B. critically read the manuscript and helped to design the study. L.G.T. provided patient samples and critically read the manuscript. E.T.V. critically read the manuscript.

Corresponding author

Correspondence to Gustavo Alencastro Veiga Cruzeiro.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This research was submitted to and approved by the HC/FMRP-USP Research Ethics Committee (CAAE no 37206114.1.0000.5440) no 15509/2016.

Informed consent

All samples were obtained after receiving informed consent from all participants included in the study.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cruzeiro, G.A.V., Lira, R.C.P., de Almeida Magalhães, T. et al. CTGF expression is indicative of better survival rates in patients with medulloblastoma. Cancer Gene Ther 27, 378–382 (2020). https://doi.org/10.1038/s41417-019-0100-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-019-0100-3

Search

Advanced search

Quick links